Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. - Wikidata - wikimedia - TriplyDB

Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.

Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.

http://www.wikidata.org/entity/Q46748088

about

Recent progress in pancreatic cancer Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians Management of borderline and locally advanced pancreatic cancer: where do we stand?New challenges in perioperative management of pancreatic cancer A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer.Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.Pancreatic cancer: pathobiology, treatment options, and drug delivery.Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation Pancreatic cancer-improved care achievable Borderline resectable pancreatic cancer: definitions and management.Therapeutic options for the management of pancreatic cancer.Current and emerging therapies for the treatment of pancreatic cancer.Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future.Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?Modeling Combined Chemotherapy and Particle Therapy for Locally Advanced Pancreatic Cancer Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer.Concurrent radiotherapy with oral fluoropyrimidine versus gemcitabine in locally advanced pancreatic cancer: a systematic review and meta-analysis.Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.Intervention of mirtazapine on gemcitabine-induced mild cachexia in nude mice with pancreatic carcinoma xenografts.A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience.Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study.Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma Predictive dosimetric parameters for gastrointestinal toxicity with hypofractioned radiotherapy in pancreatic adenocarcinoma.SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.Controversies in the management of borderline resectable proximal pancreatic adenocarcinoma with vascular involvement.Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre ra Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design.Complete Response after Treatment with Neoadjuvant Chemoradiation with Prolonged Chemotherapy for Locally Advanced, Unresectable Adenocarcinoma of the Pancreas.Current treatment options for pancreatic carcinoma.Role of radiation therapy in the management of pancreatic cancer.Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter?The role of neoadjuvant therapy in pancreatic cancer: a review.

P2860

Q24626346-D8B5963C-362D-4CCD-876C-8DF0F5119F75 Q26767041-251A3697-A3D3-4C6E-8A91-A942F99F9CF6 Q26825414-3AA4455B-FC07-4A7D-AD4B-32A97321E40A Q28082422-214E6855-3B0E-4AB5-BA71-05644521EFCF Q33400984-16E897E3-7A93-4808-B220-EFA0044E59A5 Q33408075-4055C476-817E-49DD-BCCD-A404973933F3 Q33431711-906871F5-ACBF-4A21-BEE4-32B8BD21E57D Q33558951-BB87FFDE-8150-4961-839C-DF0CBEAD6C6E Q33749460-A74BCE94-07A1-4202-AE15-3FC0A70CA6FD Q33928253-08201F02-3C1E-4A41-8A1A-3EB3F9F95D27 Q34036659-58E36547-5153-4C14-8C48-ED3A04766117 Q34067852-AF3D02DB-A44D-470A-B686-F0C5ED2E9AC5 Q34093776-F74A8090-050B-486B-AFCC-378AF4EB3AE8 Q34129346-E93BCC6D-37EC-42E4-889B-D7C136B3BEC4 Q34665177-FA489A10-1CB0-432E-807A-82B5D0BF5FA3 Q35050606-A134CD2E-0508-4159-B8E3-8242A4A291A8 Q35604577-FE66D184-19F4-4FD1-8755-7CA12C0BFC93 Q35776229-A2EAF4E7-666A-4021-8111-B2CE9CB1ED6A Q35820403-DDF8C26D-9CBE-4E77-AE23-7D1A788BA81A Q35843107-8D81746C-9AEA-402D-AD8F-0BB78D13A570 Q35860668-C07B7C4B-9F2C-4AA9-99C3-E1C439EAA19D Q36023889-D2BBE213-3847-46BC-B7E2-DEA417432C0F Q36031360-69C9D8D7-C88E-4F37-A9CC-0092824805F6 Q36211616-66A30F70-38C4-422F-ADCA-EC296957E537 Q36381222-1C7A5B36-E3DE-4BF4-890B-52146EDC92CD Q36559617-E3C24EA8-AD9C-42A7-BF4C-332A2F0DE2CE Q36668274-1FA98B32-B1D9-474F-81DB-52C7F1D8FAC3 Q36773130-AD0828B0-C480-4A57-AE0F-91407CA5ECEC Q36848552-B11E9981-F224-410F-99BE-36DC64D18B9C Q36858211-0BCF2BBC-6E5B-47D8-B3D3-A392EB554CFA Q37000899-F3BAEBC9-F540-4D17-ABC5-250B917E7C0A Q37124979-E10DD99A-F73F-4E6E-B95C-8ACCF3029177 Q37457763-EF1DE8CE-E5A8-47D3-870E-079A04F206DE Q37677864-9A01A8F9-AE8A-469F-B690-1D4E83C05606 Q37714700-1CDBE07D-31DC-4A3E-822D-13693777E40F Q37864970-D380368F-3FF6-4611-B827-E20E240338C3 Q38005349-9934F757-59FA-449B-AA6E-5A8D6103E0E8 Q38084124-B4DB901B-8E2E-443E-9C8B-C0600E34C9E7 Q38180310-9554A8A9-6229-49BA-8B8A-646BEAFD0EE3 Q38734981-0E49641D-92AB-42CB-AB5E-3112705F77E8

P2860

Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.

http://www.wikidata.org/entity/Q46748088

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Full-dose gemcitabine with con ...... a multicenter phase II trial.

@en

Full-dose gemcitabine with con ...... a multicenter phase II trial.

@nl

type

label

Full-dose gemcitabine with con ...... a multicenter phase II trial.

@en

Full-dose gemcitabine with con ...... a multicenter phase II trial.

@nl

prefLabel

Full-dose gemcitabine with con ...... a multicenter phase II trial.

@en

Full-dose gemcitabine with con ...... a multicenter phase II trial.

@nl

P1433

Q46748088-34F073B2-D7AE-488B-AAA7-761A96305641

P1476

Q46748088-59C49C1A-475B-49B9-A9AE-97007FF6F203

P2093

Q46748088-1EDEFAB3-56AD-4CCD-AEFD-1665F63FF324

Q46748088-2384EBA4-EA84-4ED1-B7DE-BC1FE15466EB

Q46748088-329B6400-457E-4669-85EE-C27ABF70BA80

Q46748088-32DA8614-DD40-4C75-AE37-F4CFD1CA12A6

Q46748088-4DF44222-7E96-499C-BF60-18C8AAEFF07C

Q46748088-501286D0-80D6-4337-88C2-FA23D4B8A886

Q46748088-5282DD37-7447-4C67-8970-F4AE6A4D37A5

Q46748088-6038974D-675D-4523-9C81-F1DBEF1519C3

Q46748088-63FDE367-DBDC-4D9C-95F2-CE061E5CC94E

Q46748088-6EDBC973-FB4F-4D8C-BABD-47D52302DF66

P304

Q46748088-B590ACCC-BE77-4A16-8992-4ED95DBC1555

P31

Q46748088-EF17CF05-8CF7-46D5-BA84-8255DA80F5B7

P356

Q46748088-DED51919-98E3-4C57-9470-9C1C06A8A635

P407

Q46748088-7425EC75-AA5C-4FD3-9BCB-F0F40796A427

P433

Q46748088-81342627-13D4-42C6-A755-6229D39B0B52

P478

Q46748088-A3B530E7-27DA-4082-B3BC-C85F1C5449DB

P577

Q46748088-B66AAB64-F1B6-42A8-8DDB-1F11D42E2149

P698

Q46748088-CEDE3DD5-FF0F-4DAF-81C9-986E89D2E14A

P921

Q46748088-AEF53358-ED0C-47F9-AE00-68F37F39A520

Q46748088-D4A43E46-7965-43BB-A570-F1BB4F6FA7C1

P356

JCO.2007.13.9014

P1433

Journal of Clinical Oncology

P1476

Full-dose gemcitabine with con ...... a multicenter phase II trial.

@en

P2093

A Bapsi Chakravarthy

http://www.w3.org/2001/XMLSchema#string

Al B Benson

http://www.w3.org/2001/XMLSchema#string

Andre A Konski

http://www.w3.org/2001/XMLSchema#string

Cornelius J McGinn

http://www.w3.org/2001/XMLSchema#string

Gary M Freedman

http://www.w3.org/2001/XMLSchema#string

John F Gill

http://www.w3.org/2001/XMLSchema#string

John P Hoffman

http://www.w3.org/2001/XMLSchema#string

Jordan Berlin

http://www.w3.org/2001/XMLSchema#string

Mark M Zalupski

http://www.w3.org/2001/XMLSchema#string

Mark S Talamonti

http://www.w3.org/2001/XMLSchema#string

P304

942-947

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.13.9014

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18281668

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

phase II clinical trial